Payment overview · 2025
General Payments
$306.35
9 reported records · 7 companies
Healthcare provider profile · identity verified
Sanjay Gupta, MD
Allopathic & Osteopathic Physicians|Internal Medicine · STEUBENVILLE, OH · NPI 1134116601
Verified facts
What the public records show
CMS Open Payments records show Sanjay Gupta, MD received $306.35 in general payments during 2025 across 9 reported records.
Stryker Corporation accounted for 55.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $170.05 | 55.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.73 | 11.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.19 | 9.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.67 | 7.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.38 | 6.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.60 | 4.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.73 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $306.35 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $170.05 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $170.05 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 760 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 353 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 307 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 282 | 64 |
| Metformin Hcl | Metformin Hcl | 279 | 72 |
| Potassium Chloride | Potassium Chloride | 276 | 54 |
| Lisinopril | Lisinopril | 268 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 205 | 54 |
| Losartan Potassium | Losartan Potassium | 203 | 55 |
| Omeprazole | Omeprazole | 196 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 184 | 48 |
| Furosemide | Furosemide | 175 | 53 |
| Eliquis | Apixaban | 156 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 151 | 104 |
| Simvastatin | Simvastatin | 140 | 36 |
| Glipizide | Glipizide | 135 | 35 |
| Gabapentin | Gabapentin | 127 | 22 |
| Buspirone Hcl | Buspirone Hcl | 117 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 31 |
| Carvedilol | Carvedilol | 113 | 25 |
| Synthroid | Levothyroxine Sodium | 106 | 21 |
| Sertraline Hcl | Sertraline Hcl | 105 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 98 | 15 |
| Meloxicam | Meloxicam | 97 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 20 |
| Trazodone Hcl | Trazodone Hcl | 86 | 18 |
| Amoxicillin | Amoxicillin | 81 | 63 |
| Fenofibrate | Fenofibrate | 80 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 16 |
| Allopurinol | Allopurinol | 73 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 16 |
| Tramadol Hcl | Tramadol Hcl | 73 | 30 |
| Glimepiride | Glimepiride | 72 | 17 |
| Atenolol | Atenolol | 70 | 17 |
| Baclofen | Baclofen | 66 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 65 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | suppressed |
| Spironolactone | Spironolactone | 59 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 50 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | suppressed |
| Lorazepam | Lorazepam | 49 | 11 |
| Levetiracetam | Levetiracetam | 47 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 47 | 12 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Alprazolam | Alprazolam | 46 | 13 |
| Prednisone | Prednisone | 45 | 21 |
| Famotidine | Famotidine | 44 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Warfarin Sodium | Warfarin Sodium | 40 | 12 |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 26 |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 23 |
| Azithromycin | Azithromycin | 25 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Insulin Lispro | Insulin Lispro | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 11 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Finasteride | Finasteride | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 11 |
| Bumetanide | Bumetanide | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $306.35 · 9 records | Stryker Corporation | CT THROMBECTOMY SYSTEM KIT, FARXIGA, FLOWTRIEVER CATHETER, S, GVOKE HYPOPEN, Ozempic, REPATHA, Rybelsus, TZIELD, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error